AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06151847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT06151847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Resection
Description: Undergo tumor resection
Study NCT05222009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
Study NCT05222009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
Study NCT04934241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Acupressure
Description: Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body
Study NCT05285956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm app
Description: Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
Study NCT05705336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Oral Product
Description: Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
Study NCT05705336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
Study NCT05142072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D3
Description: intranasal film
Study NCT05142072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: intranasal film
Study NCT06584643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gasdermin d
Description: evaluation of serum gasdermin d in vitligo patients and healthy controls
Study NCT05290857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restart DOAC within 7 days of clinical hemostasis after GI bleeding
Description: In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team).~High thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator
Study NCT05290857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
Description: In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team).~Moderate thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months~The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team.
Study NCT05341063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Education
Description: Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again.
Study NCT05341063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
Study NCT04933838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: atelocollagen
Description: This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL).
Study NCT04933838 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: atelocollagen
Description: This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL).
Study NCT04715503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging, 18F-FDG
Description: PET-MRI with 18F-FDG
Study NCT04715503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging, 68Ga-DOTANOC
Description: PET-CT with 68Ga-DOTANOC
Study NCT05767723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
Description: Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
Study NCT05767723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monotherapy: Ticagrelor alone OR Prasugrel alone
Description: Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
Study NCT04705402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes.
Study NCT04705402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
Study NCT05376787 — intervention group
Intervention type: DEVICE
Intervention: Medline NE Grounding Pad
Description: Split Universal Grounding Pads
Study NCT04845087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozonized water
Description: Irrigation of dental implants with ozonized water
Study NCT04845087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Irrigation of dental implants with water
Study NCT03824145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
Study NCT03824145 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: The attention control participants will receive a home/work organization intervention:
Study NCT06477757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Extracorporeal Circulation
Description: Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with minimally invasive extracorporeal circulation.
Study NCT06477757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Extracorporeal Circulation
Description: Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with either conventional extracorporeal circulation.
Study NCT05414201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous Injection
Study NCT05372913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Woebot for Adolescents (W-GenZD) Mobile Application
Description: Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.
Study NCT05372913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-Lite Teletherapy Group
Description: The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
Study NCT05355597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
Study NCT05355597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)
Description: Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
Study NCT05448677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezurpimtrostat
Description: Patients in the experimental arm will be instructed to take their assigned oral dose every day.
Study NCT05448677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
Study NCT05448677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
Study NCT05448677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT05448677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT06027840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline prescription will follow the standard induction period: varenicline 0.5 mg once per day for Days 1-3, varenicline 0.5 mg twice per day for Days 4-7, then varenicline 1 mg twice per day (when varenicline reaches peak efficacy for tobacco cessation). Participants will remain on varenicline for 12 weeks total. Dose adjustments (e.g., reduction to 0.5 mg twice per day if 1 mg is not well tolerated) will be allowed at the discretion of the clinical pharmacist/APRN/physician.
Study NCT06027840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Tobacco Treatment Service clinicians will deliver weekly counseling sessions, monitor participants for adverse events, and record participants' weekly cigarette and e-cigarette use. At the first counseling session clinicians will review medication proper use instructions, and potential side effects and strategies to address them at the first counseling session. Study medication refills will be distributed at 4-week intervals. Sessions will focus on quit plan preparation, supportive and practical cessation counseling, resetting quit dates, and relapse prevention.
Study NCT06027840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Change Booklets
Description: The booklet includes information on how to reduce and quit both cigarettes and e-cigarettes on their own, how to prevent relapse, how to set a quit date, and how to enroll in text-based support resources.
Study NCT05726552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter therapy
Description: Laughter therapy will be applied for 50 minutes, 12 sessions, 3 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality.~The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed.
Study NCT04232800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
Study NCT04232800 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inert, standard placebo in identical capsules to primary intervention.
Study NCT01181583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-delivered CBT
Description: This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
Study NCT01181583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-tailored Internet-delivered CBT
Description: Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
Study NCT01181583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online discussion group
Description: Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
Study NCT05286008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study NCT05286008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine at high concentration
Description: Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study NCT05286008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine and dexamethasone
Description: Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study NCT06479226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash
Description: mouthrinse
Study NCT06400264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06400264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06400264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06400264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06400264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06400264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06400264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV
Study NCT06339814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol
Description: An Eye Movement Desensitization and Reprocessing psychotherapist will hold the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol sessions, dedicated to psychoeducation, imagery exercises, stabilization techniques and the reprocessing of traumatic events. The Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol will be composed of 4 sessions of 120 minutes each.
Study NCT06339814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: Treatment As Usual condition will receive only standard support.
Study NCT06339814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment As Usual condition will receive only standard support.
Study NCT05823805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Physicians will work with a Community Health Worker (CHW) to review the data presented in their Quality Improvement reports, and triage patients for proactive outreach (e.g. No action necessary, Call patient to check-in, Arrange BP, weight and labs, Book for phone appointment, Book for in-person appointment).
Study NCT05598138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological Collection
Description: A blood sample (10 ml) will be taken for each patient included in the study.
Study NCT06215625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Description: The TIGER system provides assistance for activities of daily living. Continuous passive mode of TIGER system provides passive range of motion as warm-up. Functional mode TIGER system provides functional training.
Study NCT06215625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task-oriented training
Description: The TOT group will practice sensorimotor techniques for warming up, and then they will practice various functional tasks based on task-oriented approach.